Teva Pharmaceutical Industries Ltd. said the drugmaker will pay an undisclosed amount to settle an ongoing dispute with Amgen Inc. over the company’s generic cinacalcet hydrochloride (HCl) product.

The U.S. FDA approved Amgen Inc.’s treatment for secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis.

Vifor Fresenius Medical Care Renal Pharma obtains rights to commercialize RAYALDEE in Europe, Canada and certain other international markets; OPKO Health to receive up to $282 million in upfront and milestone payments, plus tiered double-digit royalties.

Sole issue relates to third-party manufacturing observations: no new clinical studies were requested and no safety or efficacy issues were identified.